Bambusa Therapeutics, Inc. (BBTX)
Nasdaq · Healthcare · Biotechnology
$16.07+0.44%as of Nov 5, 2026, 1:49 AM ET
- Market cap
- $800M
- 52-week range
- $13.60 – $17.42
- 52-week change
- +6.74%
- EPS (trailing)
- −$1.73
About Bambusa Therapeutics, Inc.
Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders. The company develops BBT001 for Type 2 inflammatory dermatological conditions, including atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis. It also develops BBT002, a long-acting bispecific antibody for respiratory and other Type 2 inflammatory diseases. Additionally, the company develops BBT003, a long-acting bispecific antibody for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. The company also develops BBT004 for depletion of pathogenic B cells and antibody-producing plasma cells in autoantibody-driven autoimmune diseases. The company operates in the United States, Australia, New Zealand, China, Europe, and internationally. Bambusa Therapeutics, Inc. was incorporated in 2024 and is based in Boston, Massachusetts.
Headquarters: Boston, United States · bambusatx.com